According to FutureWise analysis the market for antiarrhythmic drugs in 2023 is US$ 1.16 billion, and is expected to reach US$ 1.81 billion by 2031 at a CAGR of 5.7%.
Antiarrhythmic drugs are medications used to treat and prevent abnormal heart rhythms, also known as arrhythmias, which result from issues in the heart's electrical system. These arrhythmias can manifest as excessively fast, slow, or irregular heartbeats. Antiarrhythmics treat abnormal heart rhythms, including atrial flutter, atrial fibrillation, and ventricular fibrillation. The antiarrhythmic drugs are categorized using the Vaughan-Williams (VW) classification system, which classifies them based on their primary mechanism of action (although several agents retain properties from multiple classes).
Most antiarrhythmic medications may be administered intravenously and orally, depending on the insight of the condition. Antiarrhythmic agents drugs like procainamide and lidocaine are administered intravenously in class I since their primary use is acute treatment. An oral counterpart to lidocaine, called mexiletine, is available for oral administration. Quinidine is available in both intravenous and oral forms. Disopyramide is administered in capsules and controlled-release capsules. Oral administration is both practical and safe for drugs like flecainide and propafenone from the class I group. These drugs can effectively restore sinus rhythm in cases of recent-onset atrial fibrillation. Adenosine should be administered through proximal IV as a rapid bolus infusion, followed by a saline flush. Digoxin administration may be via the oral or intravenous route and as an intramuscular injection. Administration of antiarrhythmic drugs like amiodarone, disopyramide, dofetilide, ibutilide, and sotalol with an established risk for TdP requires continuous cardiac monitoring.
FutureWise Market Research has published a report that provides an insightful analysis antiarrhythmic drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, antiarrhythmic drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.